Sabine de Ducla

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Gϋnter von Minckwitz, Fabio Puglisi, Javier Cortés et al. · The Lancet Oncology · 2014 · 145 citations

Metastatic Breast Cancer, Chemotherapy Versus Chemotherapy, Breast Oncology +7

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

Cora N. Sternberg, Yohann Loriot, Nicholas D. James et al. · European Urology · 2019 · 132 citations · Full text

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Joseph Gligorov, Dinesh Doval, José Bines et al. · The Lancet Oncology · 2014 · 126 citations

Breast Oncology, Oncology, Maintenance Capecitabine +7

Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

Yohann Loriot, Cora N. Sternberg, Daniel Castellano et al. · European Journal of Cancer · 2020 · 58 citations · Full text

Urology, Autoimmune Disease, Genitourinary Cancer +7

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Eduard Vrdoljak, Norbert Marschner, Christoph Zielinski et al. · Annals of Oncology · 2016 · 39 citations · Full text

First-line Bevacizumab Therapy, Oncology, Breast Oncology +8